They are a blank check company whose business purpose is to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which they refer to throughout this prospectus as their initial business combination. Although they are not limited to a particular industry or geographic region for purposes of consummating an initial business combination, they intend to focus on businesses primarily operating in the life sciences sector, particularly businesses utilizing the application of machine learning techniques and structure-based drug design to improve the therapeutic development process. They will seek to capitalize on the substantial experience, relationships and scientific acumen of their management team, board of directors and advisors. Their management team will be led by CEO, Dr. Someit Sidhu, who has successfully identified R&D stage compounds and subsequently in-licensed and/or developed those compounds through critical value-creating milestones leading to several successful exits. This includes for companies such as Izana Bioscience and Akaza Bioscience for each of which Dr. Sidhu served as Co-Founder and CEO. Their COO, Dr. Tauhid Ali, launched three companies out of Takeda’s TAKcelerator, which he founded and ran at Takeda Pharmaceuticals.
Address: C/o Maples Corporate Services Limited, Po Box 309, Ugland House, Grand Cayman, Ky1-1104, Cayman Islands
Telephone: +44 7706 732212